Elevation Oncology 的 EO-3021 治疗晚期胃癌获得 FDA 快速通道资格。 Elevation Oncology receives FDA Fast Track designation for EO-3021 in advanced gastric cancer.

Elevation Oncology 的 EO-3021 已获得 FDA 快速通道资格，EO-3021 是一种针对晚期胃和胃食管结合部癌的抗体偶联物，在对既往治疗无反应的患者中表达 Claudin 18.2。 Elevation Oncology has obtained FDA Fast Track designation for EO-3021, an antibody drug conjugate targeting advanced gastric and gastroesophageal junction cancer with Claudin 18.2 expression in patients who have not responded to prior treatments. 首席执行官Joseph Ferra强调了这一指定对于加速发展的重要性。 CEO Joseph Ferra highlighted the significance of this designation for accelerating development. 该公司的目标是在2025年初扩大单疗法剂量和分享更多的试验数据,并计划在今年晚些时候开始综合研究。 The company aims to expand monotherapy doses and share more trial data in early 2025, with plans to start combination studies later this year.